<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134793</url>
  </required_header>
  <id_info>
    <org_study_id>HenanICE201901</org_study_id>
    <nct_id>NCT04134793</nct_id>
  </id_info>
  <brief_title>Correlation of Atrial Fibrillation Recurrence After Bipolar Radiofrequency Ablation With microRNA Expression</brief_title>
  <official_title>Correlation of Atrial Fibrillation Recurrence After Bipolar Radiofrequency Ablation With microRNA Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Institute of Cardiovascular Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Institute of Cardiovascular Epidemiology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recurrence rate of atrial fibrillation (AF) after bipolar radiofrequency ablation was
      about 30%. Besides the factors, left atrium diameter, the duration of AF, NT-proBNP, and
      ejection fraction(EF), some studies demonstrated that the specific microRNA expression
      (miRNA1, miRNA19,miRNA23, miRNA409 ) showed the significant change in AF patients compared
      with normal sinus patients, who underwent catheter ablation. Therefore, the correlation of
      atrial fibrillation recurrence and above-mentioned microRNA after bipolar radiofrequency
      ablation remained unclear, although bipolar radiofrequency ablation had high rate of sinus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous studies identify specific microRNA (miRNA) expression profiles associated with
      atrial fibrillation (AF), changes in plasmamiRNA expression in pre-and
      post-operativeAFpatients who have received catheterisation . The correlation of atrial
      fibrillation recurrence and above-mentioned microRNA after bipolar radiofrequency ablation
      remain poorly characterized.

      This study aimed to reveal disease-related biomarkers by detecting plasmamiRNA expression in
      AF patients, and examining the levels of AF-specific miRNAs in patients after bipolar
      radiofrequency ablation, in order to help gauge therapeutic effects and assess prognosis.

      A total of 50 Han Chinese patients with AF who had received bipolar radiofrequency ablation
      recruited to the study. Atrial fibrillation-specific plasma miRNAs were detected by
      sequencing and quantitative reverse transcription polymerase chain reaction. According to AF
      recurrence rate of about 30%, the expression levels of AF-specific miRNAs were investigated
      in15 post-operative AF patients and 35 patients with normal sinus after ablation,to explore
      changes in miRNA expression.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>atrial fibrillation recurrence rate</measure>
    <time_frame>six months after bipolar radiofrequency ablation</time_frame>
    <description>Holter ECG record</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miRNA expression difference</measure>
    <time_frame>six months after bipolar radiofrequency ablation</time_frame>
    <description>miRNA-1, miRNA-19, miRNA-23, miRNA-29,miRNA-409,</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Sinus group</arm_group_label>
    <description>Six-month follow-up, by holter ECG record，the patients keep normal sinus after atrial fibrillation radiofrequency ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atrial fibrillation recurrence group</arm_group_label>
    <description>Six-month follow-up, by holter ECG record，the patients again suffer from atrial fibrillation after atrial fibrillation radiofrequency ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>bipolar radiofrequency ablation by ablation forceps</description>
    <arm_group_label>Sinus group</arm_group_label>
    <arm_group_label>atrial fibrillation recurrence group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      microRNA from left atrium appendage
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population include persistent atrial fibrillation with mitral valve stenosis or
        regurgitation alone. Surgery procedure is mitral valve repair or replacement. Left atrium
        appendage was harvested for later tissue miRNA study. Six-month follow-up was performed by
        holter and echocardiography.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        persistent atrial fibrillation, with alone mitral valve stenosis or regurgitation

        Exclusion Criteria:

        left atrium more than 60mm ejection fraction less than 30% complicated with other valve
        disease of aortic valve stenosis or regurgitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Xiaoqiang Quan, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Henan Provincial People' Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhao, dOCTOR</last_name>
    <phone>037158681065</phone>
    <email>doctorzhao66@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leilei Zhang, doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Provincial People' Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sardu C, Santamaria M, Paolisso G, Marfella R. microRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics. 2015 Nov;16(16):1863-77. doi: 10.2217/pgs.15.117. Epub 2015 Nov 10. Review.</citation>
    <PMID>26554530</PMID>
  </reference>
  <reference>
    <citation>Philpott JM, Zemlin CW, Cox JL, Stirling M, Mack M, Hooker RL, Morris A, Heimansohn DA, Longoria J, Gandhi DB, McCarthy PM. The ABLATE Trial: Safety and Efficacy of Cox Maze-IV Using a Bipolar Radiofrequency Ablation System. Ann Thorac Surg. 2015 Nov;100(5):1541-6; discussion 1547-8. doi: 10.1016/j.athoracsur.2015.07.006. Epub 2015 Sep 19.</citation>
    <PMID>26387721</PMID>
  </reference>
  <reference>
    <citation>Gal P, Marrouche NF. Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome. Eur Heart J. 2017 Jan 1;38(1):14-19. doi: 10.1093/eurheartj/ehv514. Epub 2015 Sep 25. Review.</citation>
    <PMID>26409008</PMID>
  </reference>
  <reference>
    <citation>Briasoulis A, Sharma S, Telila T, Mallikethi-Reddy S, Papageorgiou N, Oikonomou E, Tousoulis D. MicroRNAs in Atrial Fibrillation. Curr Med Chem. 2019;26(5):855-863. doi: 10.2174/0929867324666170920151024. Review.</citation>
    <PMID>28933293</PMID>
  </reference>
  <reference>
    <citation>McManus DD, Tanriverdi K, Lin H, Esa N, Kinno M, Mandapati D, Tam S, Okike ON, Ellinor PT, Keaney JF Jr, Donahue JK, Benjamin EJ, Freedman JE. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm. 2015 Jan;12(1):3-10. doi: 10.1016/j.hrthm.2014.09.050. Epub 2014 Oct 9.</citation>
    <PMID>25257092</PMID>
  </reference>
  <reference>
    <citation>van den Berg NWE, Kawasaki M, Berger WR, Neefs J, Meulendijks E, Tijsen AJ, de Groot JR. MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications. Cardiovasc Drugs Ther. 2017 Jun;31(3):345-365. doi: 10.1007/s10557-017-6736-z. Review.</citation>
    <PMID>28752208</PMID>
  </reference>
  <reference>
    <citation>Liu T, Zhong S, Rao F, Xue Y, Qi Z, Wu S. Catheter ablation restores decreased plasma miR-409-3p and miR-432 in atrial fibrillation patients. Europace. 2016 Jan;18(1):92-9. doi: 10.1093/europace/euu366. Epub 2015 Mar 16.</citation>
    <PMID>25782451</PMID>
  </reference>
  <reference>
    <citation>Wang M, Sun L, Ding W, Cai S, Zhao Q. Ablation alleviates atrial fibrillation by regulating the signaling pathways of endothelial nitric oxide synthase/nitric oxide via miR-155-5p and miR-24-3p. J Cell Biochem. 2019 Mar;120(3):4451-4462. doi: 10.1002/jcb.27733. Epub 2018 Oct 9.</citation>
    <PMID>30302809</PMID>
  </reference>
  <reference>
    <citation>Jia X, Zheng S, Xie X, Zhang Y, Wang W, Wang Z, Zhang Y, Wang J, Gao M, Hou Y. MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. PLoS One. 2013 Dec 30;8(12):e85639. doi: 10.1371/journal.pone.0085639. eCollection 2013.</citation>
    <PMID>24386485</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Institute of Cardiovascular Epidemiology</investigator_affiliation>
    <investigator_full_name>Jian Zhao</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation, ablation, microRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

